SIRPANT IMMUNOTHERAPEUTICS

SIRPant Immunotherapeutics develops an approach to elicit tumor-specific T-cells through one of two alternative means: in vivo or ex vivo. T cells are generated in vivo by administering proprietary activated autologous macrophages that activate tumoricidal T Cells, Neutrophils, and Natural Killer Cells whilst curtailing the activity of Tregs, MDSCs, IL-10 & TGFβ. T cells are generated ex vivo by in vitro expansion of tumor-infiltrating T lymphocytes (TIL). Both in vivo and ex vivo methods result in a polyclonal immune response against multiple tumor antigens. The therapy has broad applicability for unmet needs in the treatment of solid tumors.

#SimilarOrganizations #People #Website #More

SIRPANT IMMUNOTHERAPEUTICS

Industry:

Biotechnology Medical Therapeutics

Founded:

2020-01-01

Address:

Chambersburg, Pennsylvania, United States

Country:

United States

Website Url:

http://www.sirpantimmunotx.com

Status:

Active

Contact:

610-321-3111

Total Funding:

6.22 M USD

Technology used in webpage:

SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS COVID-19 Unified Layer HostGator DNS

Similar Organizations

slingshot-biosciences-logo

Slingshot Biosciences

Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.

Current Employees Featured

robert-towarnicki_image

Robert Towarnicki
Robert Towarnicki Founder, President, Chairman & Chief Executive Officer @ SIRPant Immunotherapeutics
Founder, President, Chairman & Chief Executive Officer

Founder

robert-towarnicki_image

Robert Towarnicki

Official Site Inspections

http://www.sirpantimmunotx.com

Host Informations
Whois Informations

Loading ...

More informations about "SIRPant Immunotherapeutics" on Search Engine